## Sophie Sibéril

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7268840/publications.pdf

Version: 2024-02-01

687363 677142 25 992 13 22 citations h-index g-index papers 29 29 29 1585 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy. Advances in Experimental Medicine and Biology, 2020, 1277, 127-141.	1.6	О
2	Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1561-1572.	4.2	6
3	Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?. Frontiers in Immunology, 2017, 8, 950.	4.8	11
4	Abstract B119: Deciphering CD20 immunogenicity to generate protective anti-tumor CD4+ and CD8+ T cells. , 2016, , .		0
5	The vaccinal effect of monoclonal antibodies in cancer therapy. , 2014, , 357-372.		O
6	Abstract 3636: Anti-CD20 therapy prevents protumor regulatory T-cell expansion and triggers a memory Th1 response in tumor-bearing mice. , $2014$ , , .		0
7	Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination. Journal of Immunology, 2013, 191, 623-631.	0.8	21
8	Human iNKT and MAIT cells exhibit a PLZF-dependent proapoptotic propensity that is counterbalanced by XIAP. Blood, 2013, 121, 614-623.	1.4	97
9	Effect of zinc on human $IgG1$ and its $IgG1$ interactions. Immunology Letters, 2012, 143, 60-69.	2.5	10
10	Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. Journal of Autoimmunity, 2011, 36, 9-15.	6.5	67
11	Human X-linked variable immunodeficiency caused by a hypomorphic mutation in XIAP in association with a rare polymorphism in CD40LG. Blood, 2011, 118, 252-261.	1.4	41
12	Keeping the memory of influenza viruses. Pathologie Et Biologie, 2010, 58, e79-e86.	2.2	12
13	Activation of Human Peripheral IgM+ B Cells Is Transiently Inhibited by BCR-Independent Aggregation of Fcl³RIIB. Journal of Immunology, 2008, 181, 5350-5359.	0.8	13
14	Sialylated therapeutic IgG: a sweet remedy for inflammatory diseases?. Nephrology Dialysis Transplantation, 2007, 22, 1301-1304.	0.7	8
15	Isolation and characterization of anti-FcÂRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Engineering, Design and Selection, 2007, 21, 1-10.	2.1	75
16	Intravenous immunoglobulin in autoimmune and inflammatory diseases: More than mere transfer of antibodies. Transfusion and Apheresis Science, 2007, 37, 103-107.	1.0	30
17	FcÎ <sup>3</sup> R: The key to optimize therapeutic antibodies?. Critical Reviews in Oncology/Hematology, 2007, 62, 26-33.	4.4	86
18	Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discovery Today, 2007, 12, 548-552.	6.4	59

## SOPHIE SIBéRIL

#	Article	IF	CITATION
19	Intravenous Immunoglobulins in Autoimmune and Inflammatory Diseases: A Mechanistic Perspective. Annals of the New York Academy of Sciences, 2007, 1110, 497-506.	3.8	32
20	Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action. Journal of Clinical Immunology, 2007, 27, 233-245.	3.8	240
21	Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory $Fc\hat{l}^3R$ functions. Clinical Immunology, 2006, 118, 170-179.	3.2	77
22	Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes. Immunology Letters, 2006, 107, 58-62.	2.5	8
23	Molecular aspects of human Fc $\hat{l}^3$ R interactions with IgG: Functional and therapeutic consequences. Immunology Letters, 2006, 106, 111-118.	2.5	47
24	Fc $\hat{I}^3$ Receptor-like Activity of Hepatitis C Virus Core Protein. Journal of Biological Chemistry, 2004, 279, 2430-2437.	3.4	38
25	Future Prospects in Antibody Engineering and Therapy. , 2004, , 199-215.		O